Last edition
News about "Fitusiran Phase 3 ATLAS clinical trial"
Sanofi's Qfitlia (Fitusiran) Receives Marketing Authorisation
Sanofi’s Qfitlia (fitusiran) has received Marketing Authorisation in India for Hemophilia A and B, with or without inhibitors, addressing a critical unmet need.
Fitusiran Phase 3 ATLAS Clinical Trial | 22/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members